Categories: Technology

Rezolve Ai PLC Announces Shareholder Transfer to a New Global Institutional Investor

NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) — Rezolve Ai PLC (NASDAQ: RZLV) (“Rezolve Ai” or the “Company”) today announced that DBLP Sea Cow Limited, a shareholder associated with the estate of the late John Wagner and Rezolve Chairman and CEO Dan Wagner, has transferred 10.6 million ordinary shares of Rezolve Ai to a new leading global long-hold fundamentals-driven Institutional Investor.

This estate-related transaction was undertaken solely to settle administrative liabilities following Mr. John Wagner’s passing and represents approximately 20% of the total holdings originally held by the estate. The estate, through DBLP Sea Cow Limited, continues to retain a significant long-term shareholding in Rezolve Ai.

Rezolve Ai Chairman and CEO Daniel M. Wagner commented:
“This transaction reflects a responsible and structured estate administration following my late father’s passing. The family remains deeply committed to Rezolve Ai’s success, and we are pleased to welcome a new world-class institutional investor to our shareholder base.”

About Rezolve Ai
Rezolve Ai (NASDAQ: RZLV) is a global leader in AI-driven commerce, providing retailers and brands with proprietary technology that powers search, personalization, checkout, and omni-channel engagement. Its solutions enable businesses to harness AI for smarter customer experiences and operational efficiency. With foundational partnerships with Microsoft, Google, and Tether, Rezolve Ai is positioned to drive innovation across the $30 trillion global retail market. For more information, visit www.rezolve.com.

Investor Contact
investors@rezolve.com 

Media Contact
Rezolve Ai
Urmee Khan – Global Head of Communications
urmeekhan@rezolve.com
+44 7576 094 040

GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

2 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

2 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

2 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

2 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

2 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

2 hours ago